Spots Global Cancer Trial Database for 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)
Official Title: A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients With Newly Diagnosed Glioblastoma
Study ID: NCT05450744
Interventions
Study Description
Brief Summary: This is an open label, single arm, parallel-group, multicentre, and dose finding study to evaluate the safety of ascending radioactive dose levels of 131I-TLX101 administered intravenously in combination with best standard of care in newly diagnosed GBM patients.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Gold Coast University Hospital, Gold Coast, Queensland, Australia
Royal Adelaide Hospital, Adelaide, South Australia, Australia
Olivia Newton John Cancer Research Institute/Austin Health, Melbourne, Victoria, Australia
Institut für Nuklearmedizin und Endokrinologie, Linz, , Austria
UNMC Utrecht, Utrecht, , Netherlands
Mercy Hospital, Auckland, , New Zealand
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
